These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30161034)

  • 1. Inhibition of experimental visceral pain in rodents by cebranopadol.
    Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Christoph T; Xie JY; Porreca F
    Behav Pharmacol; 2019 Jun; 30(4):320-326. PubMed ID: 30161034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.
    Tzschentke TM; Linz K; Frosch S; Christoph T
    Pain Pract; 2017 Nov; 17(8):1032-1041. PubMed ID: 28112482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
    Schiene K; Schröder W; Linz K; Frosch S; Tzschentke TM; Jansen U; Christoph T
    Eur J Pharmacol; 2018 Aug; 832():90-95. PubMed ID: 29753041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.
    Sałat K; Jakubowska A; Kulig K
    Expert Opin Investig Drugs; 2015 Jun; 24(6):837-44. PubMed ID: 25865744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.
    Sałat K; Furgała A; Sałat R
    Inflammopharmacology; 2018 Apr; 26(2):361-374. PubMed ID: 29071457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
    Linz K; Schröder W; Frosch S; Christoph T
    Anesthesiology; 2017 Apr; 126(4):708-715. PubMed ID: 28291086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.
    Christoph T; Raffa R; De Vry J; Schröder W
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00444. PubMed ID: 30519474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited potential of cebranopadol to produce opioid-type physical dependence in rodents.
    Tzschentke TM; Kögel BY; Frosch S; Linz K
    Addict Biol; 2018 Sep; 23(5):1010-1019. PubMed ID: 28944554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain.
    Scholz A; Bothmer J; Kok M; Hoschen K; Daniels S
    Pain Physician; 2018 May; 21(3):E193-E206. PubMed ID: 29871387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.
    Raffa RB; Burdge G; Gambrah J; Kinecki HE; Lin F; Lu B; Nguyen JT; Phan V; Ruan A; Sesay MA; Watkins TN
    J Clin Pharm Ther; 2017 Feb; 42(1):8-17. PubMed ID: 27778406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOP agonist action of cebranopadol counteracts its liability to promote physical dependence.
    Ruzza C; Holanda VA; Gavioli EC; Trapella C; Calo G
    Peptides; 2019 Feb; 112():101-105. PubMed ID: 30550769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Endomorphin Analogs Are More Potent and Longer-Lasting Analgesics in Neuropathic, Inflammatory, Postoperative, and Visceral Pain Relative to Morphine.
    Feehan AK; Morgenweck J; Zhang X; Amgott-Kwan AT; Zadina JE
    J Pain; 2017 Dec; 18(12):1526-1541. PubMed ID: 28939014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain.
    Field MJ; Carnell AJ; Gonzalez MI; McCleary S; Oles RJ; Smith R; Hughes J; Singh L
    Pain; 1999 Mar; 80(1-2):383-9. PubMed ID: 10204752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers.
    Dahan A; Boom M; Sarton E; Hay J; Groeneveld GJ; Neukirchen M; Bothmer J; Aarts L; Olofsen E
    Anesthesiology; 2017 Apr; 126(4):697-707. PubMed ID: 28291085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.
    Calo G; Lambert DG
    Br J Anaesth; 2018 Nov; 121(5):1105-1114. PubMed ID: 30336855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial.
    Eerdekens MH; Kapanadze S; Koch ED; Kralidis G; Volkers G; Ahmedzai SH; Meissner W
    Eur J Pain; 2019 Mar; 23(3):577-588. PubMed ID: 30365202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.
    Tzschentke TM; Linz K; Koch T; Christoph T
    Handb Exp Pharmacol; 2019; 254():367-398. PubMed ID: 30927089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats.
    Wei H; Shang L; Zhan CG; Zheng F
    Sci Rep; 2020 Jun; 10(1):9254. PubMed ID: 32518276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.
    Kleideiter E; Piana C; Wang S; Nemeth R; Gautrois M
    Clin Pharmacokinet; 2018 Jan; 57(1):31-50. PubMed ID: 28623508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.